FB Clinical Trial Started for Drug to Prevent Preterm Birth

Free Consultation

877-262-9767

We are dedicated and compassionate

BIRTH INJURY ATTORNEYS

Get Help Today

Clinical Trial Started for Drug Designed to Prevent Preterm Birth

Clinical Trial Started for Drug Designed to Prevent Preterm Birth

Preterm birth can lead to an increased risk of birth injuries or conditions such as cerebral palsy. Swiss biopharma company ObsEva has started a proof-of-concept clinical trial of its compound OBE022 to test the compound’s ability to prevent or delay premature births. In the trial, women who start labor at 24 to 34 weeks pregnant will receive OBE222 for seven days, in addition to a standard labor-suppressing drug regimen. The trial team will monitor the expectant mothers until delivery, and both the mothers and babies for four weeks after birth. Infants will then be monitored for two years. Researchers will evaluate the therapy’s safety as well as the drug’s effectiveness in preventing preterm birth.

The following reviews from our clients do not constitute a guarantee, warranty, or prediction regarding the outcome of another legal matter. The cases mentioned in the reviews are illustrative of some of the matters previously handled by Grant & Eisenhofer involving various areas of birth injury law. These reviews are endorsements.

OK

The following reviews from our clients do not constitute a guarantee, warranty, or prediction regarding the outcome of another legal matter. The cases mentioned in the reviews are illustrative of some of the matters previously handled by Grant & Eisenhofer involving various areas of birth injury law. These reviews are endorsements.

OK CANCEL
Real Time Web Analytics